Press Releases

Press Releases

  • March 28, 2022
    Aileron Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights
  • March 22, 2022
    Aileron Therapeutics to Participate in Maxim Group 2022 Virtual Growth Conference
  • January 5, 2022
    Aileron Therapeutics Provides Business Update and Outlines 2022 Strategic Priorities to Deliver Key Milestones
  • January 4, 2022
    Aileron Therapeutics to Present at Upcoming Investor Conferences
  • December 20, 2021
    Aileron Therapeutics Issues Statement on Passing of Scientific Advisory Board Member and Nobel Laureate Robert H. Grubbs
  • November 12, 2021
    Aileron Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights
  • October 7, 2021
    Aileron Therapeutics Presents Data at AACR-NCI-EORTC International Conference Demonstrating ALRN-6924’s Activity as Radioprotective Agent in Preclinical Models of Acute Radiation-Induced Toxicity
  • September 30, 2021
    Aileron Therapeutics Announces Presentation of New Preclinical Data at Upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2021
  • September 16, 2021
    Aileron Therapeutics Presents New Clinical Data at ESMO Virtual Congress 2021 Supporting ALRN-6924’s Best-in-Class Potential as a Chemoprotective Agent
  • September 10, 2021
    Aileron Therapeutics to Present New Clinical Data at ESMO Virtual Congress 2021 Supporting Novel, Selective Chemoprotective Agent ALRN-6924